Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach
Open Access
- 1 December 2015
- journal article
- research article
- Published by Taylor & Francis in Clinical and Experimental Gastroenterology
- Vol. 8, 309-325
Abstract
Rifaximin, with its low systemic absorption, may represent a treatment of choice for irritable bowel syndrome (IBS), mainly due to its ability to act on IBS pathogenesis, through the influence on gut microbiota. The aim of the present study was to assess, by biomolecular tools, the rifaximin active modulation exerted on gut microbiota of non-constipated IBS patients. Fifteen non-constipated IBS subjects were treated with 550 mg rifaximin three times a day for 14 days. Stool samples were collected before starting the treatment, at the end of it, and after a 6-week washout period. Real-time polymerase chain reaction, denaturing gradient gel electrophoresis, and next-generation sequencing were applied to all the samples to verify and quantify possible microbial fluctuations. Rifaximin treatment did not affect the overall composition of the microbiota of the treated subjects, inducing fluctuations in few bacterial groups, balanced by the replacement of homologs or complementary bacterial groups. Rifaximin appeared to influence mainly potentially detrimental bacteria, such as Clostridium, but increasing the presence of some species, such as Faecalibacterium prausnitzii. A decrease in the Firmicutes/Bacteroidetes ratio after 14 days of treatment and bacterial profiles with higher biodiversity were observed during the follow-up compared to baseline. Rifaximin treatment, although effective on IBS symptom relief and normalization of lactulose breath test, did not induce dramatic shifts in the microbiota composition of the subjects, stimulating microbial reorganization in some populations toward a more diverse composition. It was not possible to speculate on differences of fecal microbiota modification between responders vs nonresponders and to correlate the quali-/quantitative modification of upper gastrointestinal microbiota and clinical response.Keywords
This publication has 57 references indexed in Scilit:
- Changes in soil bacterial communities and diversity in response to long-term silver exposureFEMS Microbiology Ecology, 2015
- Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic EncephalopathyPLOS ONE, 2013
- Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea‐predominant irritable bowel syndromeNeurogastroenterology & Motility, 2012
- Enterotypes of the human gut microbiomeNature, 2011
- Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model systemJournal of Antimicrobial Chemotherapy, 2010
- Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferersBMC Gastroenterology, 2009
- Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole.2009
- Statistical Methods for Detecting Differentially Abundant Features in Clinical Metagenomic SamplesPLOS Computational Biology, 2009
- RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed modelsBioinformatics, 2006
- Instability in the faecal flora of a patient suffering from food-related irritable bowel syndromeJournal of Medical Microbiology, 1987